Novel Therapy for Diabetes to be Presented at the WCIDT, London

Sep 25, 2015, 15:34 ET from MetaCure Limited

LONDON, September 25, 2015 /PRNewswire/ --

DIAMOND therapy for treatment of type 2 diabetes will be presented at the 3rd World Congress on Interventional Therapies for Type 2 Diabetes, taking place in London on September 28-30 (http://www.wcitt2d.org).  A stellar faculty of world leading experts and policy makers will discuss evidence on clinical outcomes and mechanisms-of-action of bariatric/metabolic surgery and new device-based interventions, with the overarching aim to craft an agenda of research priorities and health policy initiatives.

The latest data on gastric electrical stimulation, delivered by MetaCure's DIAMOND device, will be presented by Prof. Lebovitz as part of the Clinical Track Session on Novel Operations and Device Based Interventions, chaired by Prof. Bornstein and Prof. Morton.  A satellite session will present the principles of DIAMOND, clinical experiences and further clinical data.  Additionally, five abstracts will be presented. MetaCure's booth is located at Plaza-Suites, Level -1 (#06).

Clinical track session, Monday Sep-28

Hall A 16:30-18:30, Session 3: Clinical Track
Novel Operations and Device Based Interventions
Chairmen: Stephan Bornstein; John Morton

  • 17:45-18:00: Gastric Electrical Stimulation, Harold Lebovitz
  • 18:00-18:30: Interventional Diabetology: Between Present and Future
    Amit Patel; Shlomo Ben-Haim; Manoel Galvao-Neto; Lee Kaplan; Tomasz Klupa; Jonathan Pinkey; Stacy Brethauer

Satellite symposium, Tuesday Sep-29

Hall B 19:45-20:45
DIAMOND® by MetaCure: Minimally Invasive Treatment for Type 2 Diabetes by Electrical Modulation of Physiological Regulatory Systems
Chairman: Prof. Harold Lebovitz
Speakers: Prof. Harold Lebovitz, Prof. Wieslaw Tarnowski, Prof. Shlomo Ben-Haim
Panelists: Prof. John Dixon, Prof. George Alberti, Prof. Andreas Barthel

About type 2 diabetes 

Type 2 diabetes is a metabolic disorder characterized by hyperglycemia resulting from inadequate insulin secretion or insulin resistance.  Type 2 diabetes is the most common form of diabetes representing 90% of all cases.  Often referred to as a pandemic it is estimated that over 500 million people are affected by diabetes around the world, with management costs exceeding $600 billion annually.

About DIAMOND therapy
DIAMOND therapy is delivered by an implantable medical device as an alternative to insulin.  It is intended to treat type 2 diabetes in obese patients who are refractory to oral medication.  The safety and efficacy of DIAMOND therapy have been validated in clinical trials encompassing over 300 patients, which demonstrated it is as effective as insulin treatment while avoiding most of the side effects and avoiding the inconvenience of frequent blood tests and injections.  DIAMOND therapy is delivered by a small pacemaker-like device implanted in the abdomen to deliver gentle electrical signals to the stomach when eating, which improves glycemic control and causes weight loss.  DIAMOND has received CE mark and is approved for sale in Europe, Australia and other international markets.  DIAMOND is not approved for use in the USA.  For more information visit http://www.MetaCure.com/DIAMOND.

About MetaCure 

MetaCure, member of the Hobart Group companies, aims to provide a better way to manage type 2 diabetes, focusing on the impact on the day-to-day lives of patients.  MetaCure develops, produces and sells the DIAMOND therapy, an alternative to insulin, delivered by a proprietary implantable device system.  For more information visit http://www.MetaCure.com.

About Hobart Group
The Hobart Group accelerates ideas and develops and commercializes medical technologies targeting top healthcare markets with significant unmet needs.  The growing portfolio of companies covers the areas of cardiology, diabetes, oncology, neurology and rehabilitation.  Together, Hobart Group companies have over 200 scientists, engineers, regulatory and business experts across four continents, and benefit from the group's clinical expertise and extensive regulatory and international market knowledge across Europe, the USA and Asia.  For more information visit http://www.Hobart-Group.com.

Media inquiries
Mrs. Sharon Alon
Email: Media@MetaCure.com
Tel: +1-347-761-3350

SOURCE MetaCure Limited